single-domain antibody

single-domain antibody

A synthetic antibody that contains a single immunoglobulin chain with the variable regions of a heavy (VH) or light (VL) binding units of an immunoglobulin chain.
References in periodicals archive ?
Ablynx (Euronext: ABLX) is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease.
L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a highly specific, single-domain antibody to form a potential new targeted drug product for the treatment of lung adenocarcinoma, the most common form of cancer today.
Founded in 2001 in, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases.
Ablynx is a pioneer in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments and designed for a range of serious and life-threatening human diseases.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies[R], a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases.
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(TM), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies([R]), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases.
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies(R), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases.